A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years.

MLA

Patruno, Cataldo, et al. “A 52-Week Multicenter Retrospective Real-World Study on Effectiveness and Safety of Dupilumab in Children with Atopic Dermatitis Aged from 6 to 11 Years.” The Journal of Dermatological Treatment, vol. 34, no. 1, Dec. 2023, p. 2246602. EBSCOhost, https://doi.org/10.1080/09546634.2023.2246602.

APA

Patruno, C., Fabbrocini, G., Lauletta, G., Boccaletti, V., Colonna, C., Cavalli, R., Neri, I., Ortoncelli, M., Schena, D., Stingeni, L., Hansel, K., Piccolo, V., Di Brizzi, V., Potenza, C., Tolino, E., Bianchi, L., Manti, S., De Pasquale, R., Di Lernia, V., … Napolitano, M. (2023). A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years. The Journal of Dermatological Treatment, 34(1), 2246602. https://doi.org/10.1080/09546634.2023.2246602

Chicago

Patruno, Cataldo, Gabriella Fabbrocini, Giuseppe Lauletta, Valeria Boccaletti, Cristiana Colonna, Riccardo Cavalli, Iria Neri, et al. 2023. “A 52-Week Multicenter Retrospective Real-World Study on Effectiveness and Safety of Dupilumab in Children with Atopic Dermatitis Aged from 6 to 11 Years.” The Journal of Dermatological Treatment 34 (1): 2246602. doi:10.1080/09546634.2023.2246602.